Non-clinical assessment of cell therapy products: the perspective from five Asian countries/regions based on regulatory guidelines and the underpinning rationales.

Cytotherapy
Tomohiro YonedaYoshie Tsurumaki

Abstract

Cell-based regenerative medicine is an innovative field that can potentially alter the overall survival and quality of life of patients with devastating diseases. Several cell therapy products (CTPs) have been approved within the last two decades, and more are under development. The establishment of an effective developmental strategy in accordance with the regulatory bodies of each country/region is crucial for fast delivery of each respective CTP. In particular, facilitating investigational new drug (IND) approval is important for accelerating the transition from non-clinical to clinical research/trial phases. Here the authors compared the non-clinical prerequisites for initiating clinical studies in five Asian countries/regions (India, China, Korea, Taiwan and Japan) from an industry viewpoint. The authors first identified the differences and tried to clarify the perspectives/considerations underpinning the different requirements. The authors' findings revealed that differences in regulations and development experiences, especially with CTPs, have led to clear differences in the non-clinical study package and its corresponding study design. By sharing experiences of the research and development of CTPs among Asian countries/...Continue Reading

References

Aug 1, 2014·Expert Opinion on Biological Therapy·Chaomei ChenMeen Chul Kim
Jan 16, 2016·Immunopharmacology and Immunotoxicology·Samra Sardar, Åsa Andersson
Dec 17, 2016·Nature Reviews. Drug Discovery·Yanhong ShiShinya Yamanaka
Sep 11, 2017·Biologicals : Journal of the International Association of Biological Standardization·John PetriccianiIvana Knezevic
Dec 24, 2017·Stem Cell Research & Therapy·Alix K BerglundLauren V Schnabel
Sep 14, 2018·Stem Cells International·Ross E B FitzsimmonsCraig A Simmons
Oct 28, 2018·Cytotherapy·Natividad CuendeLaertis Ikonomou
May 6, 2019·Cells·Michael Xavier Doss, Agapios Sachinidis
May 6, 2019·Cellular and Molecular Life Sciences : CMLS·Abderrahim NajiNarufumi Suganuma
Sep 24, 2019·Frontiers in Pharmacology·Carolina Iglesias-LópezAntonio Vallano
Jan 23, 2020·Cellular and Molecular Life Sciences : CMLS·Xing-Liang FanQing-Ling Fu
Apr 9, 2020·Frontiers in Bioengineering and Biotechnology·Fengxuan HanBin Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Cell Transplantation
Yuan-Chuan ChenMing-Kung Yeh
Nature Structural & Molecular Biology
Eric M LynchJustin M Kollman
Advances in Skin & Wound Care
Kathleen D Schaum
© 2021 Meta ULC. All rights reserved